Coronavirus pandemic has pushed many countries across the globe to develop vaccines that would stop the increasing number of infected cases. According to South China Morning Post's latest report, the COVID-19 vaccine developed by Chinese scientists is already in phase two of the trial. They claimed that the trial showed significant neutralizing antibody responses for hundreds of volunteers.
The Lancet on May 22 published a research results, saying China’s COVID-19 vaccine trial, the first such vaccine to undergo phase 1 clinical trial, has been found to be well-tolerated and able to generate an immune response against the virus in humans at 28 days post-vaccination. pic.twitter.com/0asjz1XqE8 — Lin Jing 林静 (@CGCHINA_CPT) May 27, 2020
Also Read: [COVID-19] China Forces Workers to Create Facemasks, Even If It is Against People's Will
It was stated that China's vaccine is one of the two new studies that could offer new hope as medical researchers and scientists are trying to create an efficient vaccine that would counter the ongoing global pandemic. The results of the study were published by The Lancet medical journal on Monday, July 20, after the Chinese scientists have completed phase two of their trial.
Also Read: [BREAKING] Oxford's COVID-19 Vaccine Showing Promising Results as it Triggers Immune Response
The study's findings revealed that significant neutralizing antibody responses to active SARS-CoV-2 (the virus responsible for COVID-19) were induced by one injection of either a medium or even a low dose of the vaccine. The phase-one of the vaccine trial also produced immune responses, but phase-two has an enhanced range since it also includes patients who are 55 years old or older, although they have a higher risk of death from the viral disease.
"Single-dose immunization with the vaccine-induced rapid onset of immune responses within 14 days, and significant humoral and cellular immune responses within 28 days in the majority of the recipients," wrote the team of Chinese scientists. Guan Xuhua from the Hubei Provincial Centre for Disease Control and Prevention and Zhu Fengcai from the Jiangsu Provincial CDC led the team of researchers.
Other COVID-19 vaccines that currently have the potential to neutralize the viral disease
The COVID-19 vaccine of China, which resulted in a good safety profile, was developed by CanSino Biologics, a Chinese vaccine maker, and the Beijing Institute of Biotechnology. The participants in central China's Wuhan, who received the vaccine, developed mild or moderate symptoms, most commonly fever, fatigue, and headache.
5,000 Volunteers Sign up for Coronavirus Vaccine Trial in China's Wuhan City - News18 #politics https://t.co/0CuoI74uvO pic.twitter.com/iMeVUf8Afh — Sachin Kumar (@sac_isin) March 29, 2020
129 individuals participated in the vaccine trial. 72% of the patients received the medium dose, while 74% received the lower dose. One patient showed a negative reaction with the vaccine, but none of them developed serious adverse reactions.
On the other hand, Oxford's vaccine also showed promising results, which were also published by The Lancet. The vaccine produced by the Cambridge-based pharmaceutical company AstraZeneca was injected to 543 participants.The experimental coronavirus vaccine developed both humoral and cellular responses against Sars-CoV-2. The antibodies were produced 28 days after the vaccine was injected, remaining high for up to 2 months.
